Share Name Share Symbol Market Type Share ISIN Share Description
Surgical Innovations Group Plc LSE:SUN London Ordinary Share GB0004016704 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 3.25 850,666 08:00:00
Bid Price Offer Price High Price Low Price Open Price
3.20 3.30 3.25 3.25 3.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 6.33 -3.31 -0.39 30
Last Trade Time Trade Type Trade Size Trade Price Currency
15:40:44 O 500,000 3.25 GBX

Surgical Innovations (SUN) Latest News

More Surgical Innovations News
Surgical Innovations Investors    Surgical Innovations Takeover Rumours

Surgical Innovations (SUN) Discussions and Chat

Surgical Innovations (SUN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-18 15:41:503.25500,00016,250.00O
2021-06-18 14:40:463.22198,0516,369.32O
2021-06-18 13:22:343.22102,3393,290.30O
2021-06-18 11:36:353.2150,0001,605.55O
2021-06-18 09:04:093.262769.00O
View all Surgical Innovations trades in real-time

Surgical Innovations (SUN) Top Chat Posts

Surgical Innovations Daily Update: Surgical Innovations Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker SUN. The last closing price for Surgical Innovations was 3.25p.
Surgical Innovations Group Plc has a 4 week average price of 3.25p and a 12 week average price of 2.60p.
The 1 year high share price is 3.55p while the 1 year low share price is currently 1.40p.
There are currently 932,816,177 shares in issue and the average daily traded volume is 270,100 shares. The market capitalisation of Surgical Innovations Group Plc is £30,316,525.75.
buywell2: The Global Surgical Robot market has been reported to reach US $14.4 Billion by 2026 at a CAGR of close to 18% --- a high growth area to be plugged into . Growth that is being attributed to bariatric surgery and hernia repair and many other specialies BUT also along with other areas of surgery including open surgery which buywell believes Robots and SUN will move into ie to increase market share of the whole as much as is possible by cherry picking the most suitable cherries. See these testimonial videos: hTtps:// It is obvious that surgeons that have used Dexter love the system for a variety of reasons They ALL see the increased uptake of Robotic Surgery for many other areas of Surgery where it is NOT used mainly due to cost Dexter should change this And SUN now have a few irons in that fire The Dexter deal which imo is about to bear fruit plus IMO SUN are going to make Surgical Instruments for other Surgical Robotics manufacturers --- see previous posts buywell also believes there might at least one new and novel surgical instrument in the pipeline having done some midnight oil burning research recently --- that they are keeping under wraps at the moment --- probably due to competitors. imo dyor
buywell3: IMO Re what is referred to in the results as being 'sustainability' ie environment friendly and conducive to plastic waste reduction / CO2 reduction / Global Warming issues that now are affecting planet Earth. Surgical Innovations market an increasing range of Resposable™ products : Which are marketed by both Surgical Innovations and their 100% owned subsidiary Elemental Healthcare (EH) which SUN acquired around 2 years ago In a Laparoscopic Cholecystectomy, a typical fully disposable kit used in many hospitals all over the world weighs 713g. But Elemental Healthcare (100% owned by SUN) market a Surgical Innovations kit comprising of Resposable™ instruments made by Surgical Innovations and EH clients which weighs only 82g, a difference of 631g or put another way a 83% saving in throw away plastic much of which gets burned or goes to landfill. ===== Resposable™ products reduce plastic waste in Operating Theatres by 83%* ===== So if the EH/SUN range of Resposable™ Surgical Instruments were to be used then performing Laparoscopic / Keyhole / Minimally Invasive Surgery (MIS) would result in the rather staggering stat that : The equivalent of 52 plastic bottles, per surgery could be eliminated from incineration which would represent 631g of plastic in just one Laparoscopic Cholecystectomy operation . Increasingly large volumes of clinical waste are being incinerated by hospitals each year, a large percentage of this waste is from plastic materials. Hospitals are constantly under pressure to achieve cost savings and make improvements. The innovative design of Surgical Innovations Resposable™ product ranges provide a high quality reusable instrument with the clinical benefits of a small disposable element. Providing the solution for Hospitals looking to reduce costs and waste whilst maintaining reliability and quality. Disposing of a small item dramatically reduces the volume of waste and cost of disposal for the Hospital. The recurring cost of the small disposable element is also much less than a fully disposable device, providing two cost saving benefits. *We have produced a white paper which considers the role of fully disposable plastic instruments and the considerable issue of plastic waste in the Operating Theatre and examines the benefits of Resposable™ medical devices as an alternative. We also examine the consequential CO2 emissions of Operating Theatre waste management to provide a comparison aiding key decision-makers in the NHS and private healthcare. A few points of interest: « The NHS in England is responsible for around 20 million tonnes of Carbon Dioxide emissions annually and spends more than £50 million on Carbon Permits every year. (1) « Although Operating Theatres physically occupy a relatively small area in hospitals, they generate a disproportionate amount of waste. In the US, it is estimated that 20%-33% of all hospital waste is generated by the operating theatres and a single operation can generate more waste than a family of four produces in one week. (2,3) « Carbon Dioxide emissions attributable to the NHS are greater than all of the aircraft departing from London’s Heathrow Airport. (1) Conclusion: Management of waste in the Operating Theatre is a multifactorial task which should be managed around the 4 R’s (Reduce, Reuse, Recycle – Resposable™). Many of the solutions are simple – the provision of recycling bins in the OR suite so that cardboard packaging and paper IFU’s can be recycled easily. Others are much more difficult – reducing the amount of plastic waste in many operations requires a root-and-branch rethink by product manufacturers to dramatically reduce the amount of packaging and the volume of plastic used in instrumentation. In our example of the Laparoscopic Cholecystectomy, a typical fully disposable kit used in many hospitals all over the world weighs 713g. A kit comprising Resposable™ instruments weighs 82g. A difference of 631g. There are over 70,000 Cholecystectomies performed in the UK every year. If every case was converted to using Resposable™ instruments, this would represent a reduction of over 44,000kg of plastic waste per year. If a surgical instrument is equally effective, costs less than what is currently used and has the crucial benefit of dramatically reducing the CO2 footprint, then we are urging our NHS Hospitals to prioritise the consideration of this change. *Contact our UK subsidiary, Elemental Healthcare Ltd to read the full white paper and find out how to begin to reduce plastic waste in operating theatres by 83%. buywell adds : The NHS and other Heath Services in many countries have signed up to reduce their plastic waste It could be said imo that the SUN Resposable™ Trademarked brand and other Reposable Surgical Laparoscopic Instruments (Microline ) marketed to the NHS by Elemental Healthcare (EH) are at present in a 'SWEET SPOT' in that: A) Reposable products do the job just as well or better than disposable products B) A Reposable product made by SUN or sold by EH will save clients money per laparoscopic operation over its useful lifetime when compared to the cost of XXX numbers of disposable instruments used. C) Reposable products save on waste plastics and the costs of their disposal D) Reposable products help meet Government set plastic/CO2 reduction targets This is why there are a growing number of NHS Trusts switching from Disposable to Resposable™ products --- they easily solve a multitude of problems AND save monies as well. hTtps:// A VERY shrewd and well thought initiative by our new SUN CEO and COO from the Elemental Healthcare acquisition -- that will now imo pay off handsomely as the world has to go green. dyor
buywell3: ============ SUN Results as expected --- 2021 the recovery starts ============= From the Finals Chairman Nigel Rogers : "Since the beginning of 2021, we have completed several key partnership agreements to expand our reach in the US market and secure a broader range of products for UK distribution. We have also made continued progress in developing the sustainability message, and in product development, where we expect to extend the SI branded range through the launch of a number of new products in the second half of the year. "Accordingly, having demonstrated strength and resilience throughout 2020, the Group is now ideally positioned to build exciting growth as markets continue to recover." Our "sustainability in surgery" messaging continues to resonate in key markets post Covid-19, none more so than the UK with the NHS and governing medical bodies endorsing the drive for a more sustainable healthcare system. During the break in elective surgery, the Elemental team has been working closely with a number of large NHS Trusts to plan product evaluations based on the reduction of plastic waste. The evaluation process recommenced in August 2020, following the first lockdown, and has continued to be rolled out to a number of hospitals in at least five large NHS Trusts. Clearly the second wave has impacted the speed of the evaluations, but to date the outlook remains promising. Assuming these evaluations conclude positively, transition to the relevant product ranges is expected to take place during the first half of 2021. The Green Surgery Challenge, an initiative between the Company, Centre for Sustainable Healthcare ('CSH'), and the Royal Colleges of Surgeons in both England and Scotland was launched in early 2021, providing a unique platform for our portfolio of resposable devices to deliver their sustainability credentials. Additional sustainability-driven evaluations are ongoing with three major US general procurement organisations (GPOs), and the messaging is reaching an ever receptive audience around the globe. buywell comments : The decision to further adopt Reposable Surgical Instruments in regard to sustainability ie the need for a reduction in plastic waste seems imo to mean that many NHS Trusts in 2021 are going to change over to Surgical Innovations products -- likewise the USA and other parts of the world. 2021 should see a sunrise recovery imo dyor
buywell3: RNS Another Great Distribution deal and 3p beckons Microline owned by Japanese Mega Group HOYA worth gazillions $$$$ buywell adds Microline to possible acquirers of SUN as they add to their IP Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces that its wholly owned subsidiary, Elemental Healthcare Ltd ("Elemental") has signed an additional three-year exclusive GB distribution agreement with Microline Surgical Inc. ("Microline") for the distribution in Great Britain of Microline instruments. Based near Boston, MA, U.S.A. Microline designs, manufactures and distributes high quality instruments aimed at the MIS market. Its portfolio of products is complementary to those offered by SI with a focus on the Resposable (TM) ethos of cost and sustainability. Elemental has a long established relationship with Microline, and recently announced a new 5-year USA distribution agreement with Microline for the Company's range of YelloPort+Plus(TM) and YelloPort Elite(TM) Access Devices.. Adam Power, Surgical Innovations Group Development Director, says: "We are very pleased to announce an exclusive agreement for a further three years to sell products manufactured by Microline Surgical. Microline is Elemental Healthcare's longest standing distribution partner as well as our largest, and shares the philosophy of sustainability in its products which will play such an important part in hospital decision-making in the years to come." Isabelle Huysmans, General Manager Microline BV commented: "We are extremely happy to confirm the extension of the exclusive agreement for the next three years with our trusted partner, Elemental Healthcare, who embrace and embody our vision and values completely. Together we will continue to work passionately on sustainability to provide solutions to improve the quality of life for everyone. "
buywell3: The list of Institutional Investors in SUN reads better than some FTSE100 stocks The percentage of SUN that is owned by these larger Investors is now very large So getting shares for the PI in any quantity is not too good and as better news of Distribution deals comes that gets harder still eg expect news re Dexter and other Robotics soon The market in the USA for Fix8 in 2023 will imo earn SUN about $1M Which means according to my maths === see previous posts re Trocar sales and SUN surgical instrument sales with USA Distributors Microline and Alder ( both 5yr deals) Means SUN should in buywells opine be turning over circa $6M plus from the USA alone in 2023 That is without new products which will be coming to market over the next 12 months -- Trocars and others This stock has only just started to play catch up imo That AMS has not moved to acquire it at these levels has surprised buywell , when Fix8 has FDA approval in 2022 --- then the Mkt Cap of SUN should have risen a fair bit higher than it is today dyor
buywell3: yes it is called the buywell effect lol SUN along with its Elemental Healthcare acquisition which by the way have a very good new website with a lot of new products added Plus re buywell's posts on here and on the BUY thread about Covid-19/Obesity/Bariatric Surgery hTtps:// When aerosol spread is recognized by the CDC and WHO and EMA etc as the biggest cause of Covid-19 transmission --- then the focus on the super spreaders ie obese people 20% of whom in a recent study were responsible for over 80% of the aerosol output of the entire group --- actions to reduce obesity by bariatric keyhole surgery ie proactive and quick --- will be needed as Covid-19 keeps mutatin and producing more transmissible and lethal variants Check out these products hTtps:// SUN imo is cheap at this share price as it is and has been a profitable company in a good niche market where barriers to entry are now very high. Plus as recent RNS's have shown , SUN is recognized as a quality maker and supplier of MIS (keyhole) surgical instruments and materials and devices needed to carry out such surgery --- their NHS sales imo are helping hugely now in gaining sales traction in the USA and ROW 4p chartwise in imo very doable --- buywell notes the Advanced Medical Solutions (AMS) LiquiBand Fix8 initiative in America is coming along, today AMS said: 'The clinical trial for the LiquiBand Fix8 (R) US Pre-Market Approval process is progressing well and both trial results and surgeon feedback has been positive. It is expected that patient procedures will be complete in 2021 followed by FDA filing in 2022. US approval would be a significant milestone for the Group, being the first product of its type to enter the $250 million US hernia fixation market. ' 'This positive progress supports efforts to secure more specialist partners for LiquiBand Fix8 (R) which is expected to drive much stronger growth for this category globally as elective surgery volumes recover. ' hTtp:// buywell has long held the opinion that AMS could be a buyer of SUN as it has recently renewed the rights to sell LiquBand Fix8 instrument which is made by SUN and remember SUN 100% own the IP of the device ---- but there are now several others
buywell2: That chart above would imo suggest chartwise 4p as the next resistance level to be tested if the uptrend now started continues A vaccine led return to normal NHS operations commencements would help as the backlog needs to be addressed for many awaiting Keyhole surgery must have doubled or more in the last 9 months to 10 months The recent two USA Distribution deals will imo also keep the share price heading North News of a Dexter Deal with the NHS soon should imo get 3p tested More if it involves circa 4 or 5 NHS Hospital Trusts which imo would indicate a more general NHS consensus towards a likely growing adoption of the technology and the preference of a lease model rather than the more costly outright purchase of such robotic machines which can cost around $1M apiece buywell would like to draw readers attention to something which has been said by SUN recently , namely : " Collaborations on early stage projects with a number of robotic manufacturers who have recognised the Company's expertise in access devices and instruments; these represent exciting opportunities over the longer term " Notice the plural usages -- ' a number of robotic manufacturers ' This imo means NEW robotic manufacturers other than Distalmotion the maker of Dexter Since SUN are the UK Distributor for Dexter/Distalmotion ie sell into the NHS IMO this could mean other robotics sales possibilities involving other robotics manufacturers in other countries , possibly the design and production of NEW bespoke innovative Keyhole surgical instruments designed specifically or tailor made to suit the individual robot hand and for a specific type of surgery or application within the Minimal Invasive Surgery area the robot is to be used . The use of robots for keyhole surgery in an endemic or pandemic Health Service setting looks set to accelerate given virus aerosol spread within operating theatres and ICU's and various Hospital rooms coupled with staffing burnout/shortages/mental stress and sickness issues. Robots can help doctors and nurses minimise virus inhalation as best as possible remembering that a number of patients undergoing surgery from now on will be asymptomatic patients and will not have tested positive for Covid-19 or any other virus or variant of a virus they might have in the future. A large hospital-wide screening programme has shown that 30 of 61 (49%) SARS-CoV-2 positive Hospital Care Workers HCWs were asymptomatic. The use of robots for both surgery procedures and disinfection control is a must imo to tackle Hospital acquired Covid-19 as it is a major problem: Minimising direct contact between patients and Hospital staff who then might get infected themselves and pass on the virus to other patients of days that follow is an obvious area needing attention. Robots do this as they can be controlled from many metres away in an adjoining room or clean air controlled cubicle. 18th December 2020 A Health Service Journal analysis of NHS England data found that around one in four covid cases was probably caught by hospital inpatients initially admitted for other reasons. The rates were over one in three in some hospitals and had risen by 35% in one week. NOT GOOD htTps:// This can not be allowed to continue during virus surges in the future : At some trusts, the weekly total of likely hospital-acquired covid-19 infections has more than doubled since last week htTps:// ----------------------------------------------------------------------------- ---- The size and nature of the problem of Hospital acquired Covid-19 --- ----------------------------------------------------------------------------- Nosocomial transmission is also known as Hospital transmission Nosocomial meaning ---- originating in a hospital. 6th January 2021 Nosocomial transmission and outbreaks of coronavirus disease 2019: the need to protect both patients and healthcare workers hTtps:// Nosocomial outbreaks of SARS-COV-2 can be as high as 60% This is not good enough and the use of robots can help get that percentage down dyor
buywell2: They did not put a number on the recent 5yr USA Trocar Deal with Microline unlike the one with USA Adler Surgical also 5yr and valued at $12M The market for Trocars is big in the USA , also specialist Microline in a BIG player in America and was not selling or making its own brand of Trocar That it chose SUN speaks volumes , the trocar market for SUN through Microline could be arguably bigger as SUN has yet newer trocars soon to come to market which presumably Microline will also sell into the USA Perhaps a number might then be put on the 5yr sales deal , $12M ? If so that would be $24M USA sales over 5 years = Nearly $5M a year added to turnover or around 3.5M GBP a year of which imo at least 1M would be profit Then there is the ROW to sell the new Trocar range into plus other new products coming to market
buywell3: To any newbe to SUN A couple of points to think about from here on 1) Planned operations in the NHS have been getting cancelled for the last few years around the winter flu season when beds get full in hospitals. This has been made worse by Covid-19 and looks now imo to be an ongoing issue for the NHS and Government to sort out . 2) Cancellation of operations does NOT however mean that the work is lost unless of course the patient dies --- which regards to MIS the area of SUN operations is imo unlikely in the vast majority of cases so what it means is that the backlog of work stacks up It is fairly obvious now that there is a bed shortage in ICU's and also a staff shortage Ditto for nurses across other wards Not enough doctors, surgeons or Hospitals to cope with what will be the Covid endemic as we all learn to live a vaccine existance getting what imo will be at least 2 Covid-19 jabs a year until a cure is found . So the Government has to invest in technologies that can clear the backlog and keep pace with increase in work as more sick patients arrive at Hospitals MIS reduces LOS in Hospitals so it frees up beds and allows more patients to receive treatment MIS results in less complications after surgery so it saves money re claims and is better in patient outcomes a win/win MIS Robotic surgery has the potential to increase the output of operations carried out as robots do not get tired or go sick or take annual leave buywell expects to see a RNS from SUN very soon now to say that a certain Hospital/s with NHS Trust XXXX has leased yyy Dexters buywell expects such an RNS to be accompanied by investors buying SUN as such news sinks in buywell expects further RNS's to follow as other Hospitals and other NHS Trusts follow with a similar result
van zandt: May I say the same to most. I feel such excitement coming on!! No. Nothing to do with SUN share price. as ever regards VZ
Surgical Innovations share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Surgical I..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210619 07:22:35